Trial · NCT06542393
PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)
NCT06542393, Phase 2, Unknown, Federal University of São Paulo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG). Trials, record NCT06542393. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06542393
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- PBM as Strategy to CABG Anemic Patients Bypass Graft (CABG)
- NCT number
- NCT06542393
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 120 participants, estimated
- Lead sponsor
- Federal University of São Paulo
- Conditions
- Anemia, Coronary Disease, Coronary Artery Disease, Coronary Stenosis, Coronary Occlusion, Systemic Inflammatory Response, Bleeding, Epigenetic Disorder
- Interventions
- Erythropoietin, blood transfusion
- First posted
- 2024-08-07
- Last updated
- 2024-08-07
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mean number of units of Red Blood Cells (RBC) | Until perioperative day 3 | Compare the need of blood transfusion in the perioperative period |
| Secondary | Length of ICU stay | From time of admission after surgery to time of clinical conditions of discharge (time of ICU medical discharge, not time of ICU room exit). Up to 240 hours. | Hours |
| Secondary | Length of hospital stay | From time of ICU medical discharge until time of Hospital discharge (Up to 14 days). | Days |
| Secondary | Length of mechanical ventilation | From time of intubation by anesthesia team until time of extubation by ICU team (Up to 240 hours). | Hours |
| Secondary | Need of Dyalisis (Acute Kidney Disease) | Based on KDIGO classification of Acute Kdney Injury, level III of the classification. (Up to 120 hours from ICU admission, accountable from the time Dyalisis is indicated). | Needing of dyalisis in peoperative period |
| Secondary | Perioperative infection | Until perioperative day 3 | Anytype |
| Secondary | Bleeding | From time of admission on ICU until hour 24th after admission (accountable amount from how many chest tubes the patient was admitted). | Thorax drain tubes bleeding (ml) |
| Secondary | Epigenetics alterations | Until perioperative day 3 | . Differentially methylated regions (DMRs) and differentially methylated loci (DMLs) will be considered to determine if these regions are hypermethylated or hypomethylated in the comparison between groups. |
| Secondary | Inflammatory response | Until perioperative day 3 | A total of 25 μl of serum per patient will be used for the detection of the following analytes: IL-1β, IL-6, IL-10, TNF-α, CRP, and NT-ProBNP. |
| Secondary | Perioperative myocardial infarction | Until perioperative day 3 | According to type 5 Myocardial ischemia |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers42
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06542393
GET https://conductscience.org/api/trials/v1/NCT06542393/papers?page=2